TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03785652
Drug: LY03005 extended-release tablets 160 mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast
Study: NCT03785652
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast
Study: NCT02032823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
Study: NCT03914625
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03914625
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03914625
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT01666067
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01666067
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03914625
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03914625
Drug: Mercaptopurine Oral Suspension
Normalized name: mercaptopurine Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00796887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: NCT03914625
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT03914625
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT02276027
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
Study: NCT04066192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A medically inert placebo medication will be used as described in the study arms.
Study: NCT02276027
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
Study: NCT02276027
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
Study: NCT02276027
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
Study: NCT04288323
Drug: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Normalized name: DIETHYLENETRIAMINE PENTAACETIC ACID
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
Study: NCT02099071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01220128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
Study: NCT03745820
Drug: BIIB104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00348933
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
Study: NCT00716833
Drug: Etoricoxibe
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
Study: NCT00716833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
Study: NCT02984072
Drug: Aqueous Cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01220128
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
Study: NCT01220128
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT01220128
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Study: NCT01211431
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathécale morphine is used for post-cesarean pain control
Study: NCT01211431
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
Study: NCT00338897
Drug: SR123781A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00227734
Drug: capecitabine and oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine and oxaliplatin without cetuximab
Study: NCT00649311
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
Study: NCT00740805
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00740805
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02508649
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02981628
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02981628
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT02981628
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT03751124
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
Study: NCT03751124
Drug: Placebo for E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
Study: NCT00408135
Drug: telithromycin (HMR3647)
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01246908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice per day for six weeks.
Study: NCT01185301
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: weekly oral capsule dosing
Study: NCT04081259
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
Study: NCT03876301
Drug: Standard of Care FVIII Replacement therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Study: NCT00401362
Drug: SC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00924781
Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
Study: NCT01322776
Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
Study: NCT02208778
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 27 participants will be allocated to Remifentanil infusion
Study: NCT02208778
Drug: Placebo (for Remifentanil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
Study: NCT02208778
Drug: Placebo (for Duloxetine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
Study: NCT00865423
Drug: NEURONTIN® 800 mg Tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Study: NCT01566695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
Study: NCT01104532
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01512667
Drug: MK-0822
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
Study: NCT02815280
Drug: FMX-101, 4% minocycline foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
Study: NCT03594175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
Study: NCT02483871
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03513445
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Study: NCT01253824
Drug: NPC-01
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
Study: NCT01253824
Drug: IKH-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
Study: NCT00770146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
Study: NCT00918060
Drug: Camella sinensis gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical effect of locally-delivered gel between Camella sinensis and placebo
Study: NCT05023824
Drug: alpha-blocker or 5-ARI withdrawal
Normalized name: 5.alpha.-hydroxy laxogenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of either alpha-blocker or 5-ARI
Study: NCT05023824
Drug: Maintenance of alpha-blocker and 5-ARI
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of alpha-blocker and 5-ARI
Study: NCT01836874
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
Study: NCT00040456
Drug: Mg Pidolate
Normalized name: Pidolic acid
DrugBank: Pidolic acid (DB03088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
Study: NCT03800550
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablet will be administered, orally.
Study: NCT00512070
Drug: olanzapine and melatonin
Normalized name: olanzapine and samidorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
Study: NCT00040456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
Study: NCT01864356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01792570
Drug: RPV + DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to dual HAART
Study: NCT01792570
Drug: continue the PI/r-containing HAART.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue the on-going triple drug HAART.
Study: NCT03976869
Drug: AZD7594
Approvals — FDA: no, EMA: no, PMDA: no
Description: During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
Study: NCT02829541
Drug: BIIB068
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02829541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00396448
Drug: CP-945,598 Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Study: NCT00396448
Drug: CP-945,598 Treatment A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Study: NCT00396448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Study: NCT01203852
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
Study: NCT02536183
Drug: Lyso-thermosensitive liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
Study: NCT01433276
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
Study: NCT00961571
Drug: sunitinib and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
Study: NCT03021161
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
Study: NCT01613170
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
Study: NCT02622607
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
Study: NCT00199095
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199095
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199095
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01827072
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched tablet dialy
Study: NCT04395950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two tablets daily in the morning for 6 weeks
Study: NCT01556165
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, once daily, orally
Study: NCT03980561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive medication
Study: NCT02066688
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
Study: NCT02066688
Drug: folic acid calcium vitamin D3
Normalized name: cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
Study: NCT02066688
Drug: calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
Study: NCT01811121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
Study: NCT03791255
Drug: Calcium silicate liner
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
Study: NCT03791255
Drug: Calcium hydroxide liner
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
Study: NCT03943407
Drug: Zyclara 3.75 % Topical Cream
Normalized name: Zyclara 3.75 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
Study: NCT02249247
Drug: Medium dose of BIIL 284 BS tablets
Normalized name: betamethasone 0.284 MG/ML / gentamicin 0.57 MG/ML [Betagen brand of Betamethasone and Gentamicin]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249247
Drug: High dose of BIIL 284 BS tablets
Normalized name: betamethasone 0.284 MG/ML / gentamicin 0.57 MG/ML [Betagen brand of Betamethasone and Gentamicin]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00402233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no